Hemoglobinopathies Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 7.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Hemoglobinopathies Treatment Market Analysis
The global hemoglobinopathies treatment market was studied and projected to grow with a CAGR of nearly 7% over the forecast period. The growth is primarily due to an increase in the cases of hemoglobinopathies, coupled with growing awareness pertaining to hemoglobin disorders. According to the World Health Organization, about 1.1% of the couples globally are at the risk of having a child with hemoglobin disorder and prevalence was estimated at 2.55 per 1000. In addition, the presence of strong product pipeline for the treatment of hemoglobinopathies and continuous efforts from the market players and government in developing the new therapies for the same are anticipated to boost the market growth. However, low awareness related to the hemoglobinopathies in low and some of the middle-income countries is anticipated to hamper the market growth. Moreover, the initiatives such as newborn screening for detection of potential disorders are lead by the government and private organizations are anticipated to fuel the market growth for hemoglobinopathies treatment.
Hemoglobinopathies Treatment Market Trends
This section covers the major market trends shaping the Hemoglobinopathies Treatment Market according to our research experts:
Sickle Cell Anemia Anticipated to Grow at Significant Rate
- Sickle cell anemia refers to the group of blood disorders that cause misshape of red blood cells. This makes difficult for RBC to carry oxygen to different organs and tissues. Poor oxygen in the blood may lead to severe pain syndromes, necrosis and bacterial infections.
- The growing number of cases with sickle cell anaemia globally, coupled with the presence of a robust pipeline of drugs for the treatment of disease is anticipated to boost the segment growth over the forecast period.
- Drugs used for symptoms of hemoglobinopathies treatment include antibiotics, analgesics, ACE inhibitors. Further, Blood transfusion or stem cell therapy is one of the preferred treatments for hemoglobinopathies. Moreover, increasing research on the treatment of hemoglobinopathies such as gene therapies advancing the market growth.
- The World Health Organization has estimated that each year about 300000 babies are born with a severe form of inherited blood disorders, and 5% of the world population carries trait genes for haemoglobin disorders, mainly, sickle cell anaemia and thalassemia. Thus the growing incidence of hemoglobinopathies coupled with the rise in R&D investment for the development of treatment options expected to boost the market over the forecast period.
Europe is Anticipated to Have Significant Growth
Among the regional segments, Europe is anticipated to have significant market growth over the forecast period. The growth is attributed to a high number of hemoglobinopathies cases especially in Mediterranean countries, new product launches and growing awareness regarding the disorder. North America is anticipated to have notable market growth owing to well-established healthcare infrastructure for early diagnosis and treatment of hemoglobinopathies and initiatives by the government and non-government organizations to increase the awareness.
Hemoglobinopathies Treatment Industry Overview
Global hemoglobinopathies treatment market is moderately fragmented and competitive. Market players are focusing on new product launches, product innovations and geographical expansion. For instance, in May 2017, Sangamo Therapeutics and Pfizer announced a collaboration for the haemophilia A gene therapy. The key market players operating in the market include Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc. EMI Holding, Inc. and Celgene Corporation among others.
Hemoglobinopathies Treatment Market Leaders
-
Sanofi S.A.
-
Global Blood Therapeutics, Inc.
-
bluebird bio, Inc.
-
EMI Holding, Inc.
-
Celgene Corporation
*Disclaimer: Major Players sorted in no particular order
Hemoglobinopathies Treatment Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Increasing Prevalence of Genetic Blood Disorders
-
4.2.2 Presence of Robust Pipeline
-
-
4.3 Market Restraints
-
4.3.1 Low Awareness Regarding Hemoglobinopathies
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Treatment
-
5.1.1 Stem Cell Therapy
-
5.1.2 Blood Transfusion
-
5.1.3 Iron Chelation Therapy
-
5.1.4 Others
-
-
5.2 By Application
-
5.2.1 Thalassemia
-
5.2.2 Sickle Cell Anaemia
-
5.2.3 Others
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States
-
5.3.1.2 Canada
-
5.3.1.3 Mexico
-
-
5.3.2 Europe
-
5.3.2.1 Germany
-
5.3.2.2 United Kingdom
-
5.3.2.3 France
-
5.3.2.4 Italy
-
5.3.2.5 Spain
-
5.3.2.6 Rest of Europe
-
-
5.3.3 Asia-Pacific
-
5.3.3.1 China
-
5.3.3.2 Japan
-
5.3.3.3 India
-
5.3.3.4 Australia
-
5.3.3.5 South Korea
-
5.3.3.6 Rest of Asia-Pacific
-
-
5.3.4 Middle-East and Africa
-
5.3.4.1 GCC
-
5.3.4.2 South Africa
-
5.3.4.3 Rest of Middle-East and Africa
-
-
5.3.5 South America
-
5.3.5.1 Brazil
-
5.3.5.2 Argentina
-
5.3.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Sanofi S.A.
-
6.1.2 Global Blood Therapeutics, Inc.
-
6.1.3 bluebird bio, Inc.
-
6.1.4 EMI Holding, Inc.
-
6.1.5 Celgene Corporation
-
6.1.6 Gamida Cell
-
6.1.7 Prolong Pharmaceuticals, LLC.
-
6.1.8 Sangamo Therapeutics Inc.
-
6.1.9 Silence Therapeutics
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Hemoglobinopathies Treatment Industry Segmentation
As per the scope of the report, hemoglobinopathies is the group of blood disorders which are inheritable, including thalassemia, sickle cell anaemia and others.
| By Treatment | |
| Stem Cell Therapy | |
| Blood Transfusion | |
| Iron Chelation Therapy | |
| Others |
| By Application | |
| Thalassemia | |
| Sickle Cell Anaemia | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Hemoglobinopathies Treatment Market Research FAQs
What is the current Hemoglobinopathies Treatment Market size?
The Hemoglobinopathies Treatment Market is projected to register a CAGR of 7% during the forecast period (2024-2029)
Who are the key players in Hemoglobinopathies Treatment Market?
Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc., EMI Holding, Inc. and Celgene Corporation are the major companies operating in the Hemoglobinopathies Treatment Market.
Which is the fastest growing region in Hemoglobinopathies Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Hemoglobinopathies Treatment Market?
In 2024, the North America accounts for the largest market share in Hemoglobinopathies Treatment Market.
What years does this Hemoglobinopathies Treatment Market cover?
The report covers the Hemoglobinopathies Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Hemoglobinopathies Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Hemoglobinopathies Treatment Industry Report
Statistics for the 2024 Hemoglobinopathies Treatment market share, size and revenue growth rate, created by 糖心vlog传媒鈩� Industry Reports. Hemoglobinopathies Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
